Clinical Trial: ALLIANCE A031704

ALLIANCE A031704

Status: Closed

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Eligible for screening study DCP 001

A031704 closed to accrual  effective May 15, 2024.